{"entity":{"id":"dbcg-82bc","kind":"trial","name":"DBCG 82b and 82c","aka":[],"tldr":"The Danish postmastectomy trials proved that radiotherapy to the chest wall and nodes after mastectomy not only prevents local recurrence but saves lives in women with node-positive disease.","summary":"DBCG 82b randomised 1,708 premenopausal women with high-risk breast cancer to CMF chemotherapy with or without postmastectomy radiotherapy; 82c randomised 1,375 postmenopausal women to tamoxifen with or without radiotherapy. In 82b, ten-year locoregional recurrence fell from 32 to 9 percent and overall survival rose from 45 to 54 percent (Overgaard and colleagues, New England Journal of Medicine 1997); 82c showed the same pattern (Lancet 1999). Together with the British Columbia trial they established postmastectomy radiotherapy for node-positive disease.","status":"positive","asOf":"2026-09-17","links":[{"label":"NEJM 1997","url":"https://doi.org/10.1056/NEJM199710023371401"}],"tags":["radiation-wave4"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["cyclophosphamide","methotrexate","fluorouracil","tamoxifen"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"phase":"3","setting":"High-risk breast cancer after mastectomy: postmastectomy radiotherapy added to systemic therapy (CMF in premenopausal, tamoxifen in postmenopausal women) versus systemic therapy alone","sponsor":"Danish Breast Cancer Cooperative Group","result":"82b: 10-year locoregional recurrence 9% vs 32%; overall survival 54% vs 45%.","yearReported":1997,"enrolled":3083,"outcomes":[{"endpoint":"Overall survival at 10 years (82b)","primary":true,"unit":"%","arms":[{"name":"CMF plus postmastectomy radiotherapy","n":852,"value":54},{"name":"CMF alone","n":856,"value":45}]}]},"route":"/trials/dbcg-82bc/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"methotrexate","kind":"drug","name":"Methotrexate","route":"/drugs/methotrexate/"},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"}]}}